STAT3 and prostate carcinoma: JMJD1C also reportedly demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis to participate in the progression of prostate cancer via an upregulation of TNF-α and mediate myocardial hypertrophy via angiotensin II (Ang II) [133,137,138].